Oppenheimer Maintains Outperform on Viking Therapeutics, Raises Price Target to $138
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Viking Therapeutics (NASDAQ:VKTX) and raises the price target from $116 to $138.
March 27, 2024 | 11:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson maintains an Outperform rating on Viking Therapeutics and raises the price target from $116 to $138.
The increase in the price target by a reputable analyst suggests a strong confidence in Viking Therapeutics' future performance. This is likely to positively influence investor sentiment and potentially lead to a short-term increase in VKTX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100